Product introduction:
Vorolazan fumarate belongs to potassium ion (K +) competitive acid blocker (p-cab), which is a reversible proton pump inhibitor. After entering the human body, it stops the secretion of gastric acid by inhibiting the combination of K + and H + - K + - ATPase (proton pump) in the last step of acid secretion of gastric parietal cells. It has a strong and lasting effect of inhibiting gastric acid secretion.
CAS:881681-01-2
Molecular formula: C21H20FN3O6S
Molecular weight: 461.46
Structural type:
Chemical property: white to beige solid
Product purpose: Treat duodenal ulcer, gastric ulcer and reflux esophagitis, gastric ulcer or recurrent duodenal ulcer caused by low-dose aspirin. Eradication of Helicobacter pylori, adjuvant treatment of the following diseases: gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, early gastric cancer, Helicobacter pylori infectious gastritis.